BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review

IF 5.5 2区医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-11-05 DOI:10.1016/j.critrevonc.2024.104551

Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang

{"title":"BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review","authors":"Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang","doi":"10.1016/j.critrevonc.2024.104551","DOIUrl":null,"url":null,"abstract":"<div><div>Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton’s tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient’s CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104551"},"PeriodicalIF":5.5000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002944","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton’s tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient’s CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

BCMA CAR-T诱导浆细胞性淋巴瘤同步转化为慢性淋巴细胞白血病的患者获得完全和持久缓解：病例报告和文献综述。

尽管布鲁顿酪氨酸激酶抑制剂的靶向治疗显著改善了慢性淋巴细胞白血病（CLL）的预后，但在创新疗法时代，里氏转化仍然是一个严重的风险。我们报告了一例罕见病例，一名61岁的男性患者在接受伊布替尼治疗后，CLL转变为同步克隆相关性浆细胞性淋巴瘤（PBL）。在COVID-19期间，患者停止服用伊布替尼，导致病情恶化。组织学检查显示，右锁骨上肿块中存在PBL，CLL已侵入骨髓。患者在接受了三个周期的CHP（环磷酰胺、多柔比星和泼尼松）治疗后，又接受了venetoclax和brentuximab vedotin治疗。接受 BCMA CAR-T 细胞治疗后，患者病情完全缓解。对于预后较差、治疗选择较少的PBL转化，我们的研究结果建议使用BCMA CAR-T和新型靶向药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.